# Study of BMS-986012 in Subjects With Small Cell Lung Caner

> **NCT02949895** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 7 (actual)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** BMS-986012
- **DRUG:** Cisplatin
- **DRUG:** Etoposide

## Key facts

- **NCT ID:** NCT02949895
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-29
- **Primary completion:** 2017-08-29
- **Final completion:** 2017-08-29
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2019-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02949895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02949895, "Study of BMS-986012 in Subjects With Small Cell Lung Caner". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02949895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*